NVO Novo Nordisk A/S : Bullish and Bearish Analyst Opinions

NVO has been on a prolonged downtrend. The stock has reached a level where contrarian buyers are stepping in, expecting a mean-reversion bounce. A speculative bottom-fishing play anticipating exhaustion of sellers. "Catching a falling knife" if the fundamental reasons for the downtrend persist.

Novo launched a superior dose of Wegovy (HD) with better efficacy, at a competitive price point, and expanded access via telehealth partnerships. This strengthens Novo's competitive moat against Eli Lilly and could drive market share growth and revenue upside, potentially not yet reflected in the stock price ahead of critical May 5th earnings. Positive product cycle news and strategic moves create a near-term catalyst for the stock, supporting the author's view of potential undervaluation. Earnings miss on May 5th; stronger-than-expected competitive response from Eli Lilly (LLY); regulatory pushback on pricing or distribution.

Speaker states Wegovy pill has "injectable type efficacy" (17% weight loss), a strong tolerability profile (2% discontinuation rate), and is the "only peptide in a pill." Highlights a unique subscription model and strategy focused on new prescribers and patients. Superior product profile (efficacy, tolerability, oral administration) and innovative commercial strategy (subscription, dynamic pricing) are key to maintaining momentum and market leadership against new competitor Lilly. Confident in Novo Nordisk's ability to sustain its trajectory and competitive edge in the GLP-1 market. Lilly's pill gains overwhelming market share or significant adverse events are reported for Wegovy.

Jamey Millar stated that Novo Nordisk pioneered the weight-loss drug category, with Wegovy pill achieving 17% weight loss efficacy and strong tolerability, and introduced a unique subscription model to improve adherence and affordability. These product advantages—superior efficacy, tolerability, and innovative consumer-centric pricing—are expected to sustain strong demand and market leadership, even as competitors like Eli Lilly enter the market. LONG on Novo Nordisk due to its first-mover edge, proven product performance, and strategic initiatives that enhance accessibility and patient retention in a growing market. Increased competition from Eli Lilly and other entrants, potential regulatory hurdles, adverse event reports, or shifts in consumer preference that could erode market share.

The author is issuing a downgrade on Novo Nordisk, signaling an expectation for the stock to underperform based on a revised negative outlook.

The tweet mentions Eli Lilly and Novo Nordisk without providing specific sentiment or context.

The author is reminding shareholders to submit their votes for NVO and LLY before the market closes.

The tweet contains incoherent text and provides no actionable financial sentiment regarding the mentioned tickers.

The author predicts that LLY's orforglipron approval will negatively impact NVO's stock price.

Novo Nordisk's aggressive pricing and subscription strategy is a direct competitive move to regain market share from LLY, which could positively impact its stock price.

Novo's UBT251 (triple-agonist) shows promising phase 2 data (up to 19.7% weight loss, 2.16% HbA1c reduction), making it competitive with Lilly's retatrutide. The market consensus values Novo as overly reliant on semaglutide and behind Lilly, creating a valuation disconnect if UBT251's potential is recognized. Novo's next-gen pipeline is deeper than priced in, and its United Biotechnology partnership strengthens its long-term position, particularly in China. Phase 2 data is early; glucagon-related side effects may appear; global scalability and phase 3 results are unproven.

The author argues that the market for body composition drugs is significantly larger than current weight loss solutions suggest.

Hims' move to sell branded GLP-1s offers a legitimacy boost but introduces margin pressure, creating a balanced outlook.

The tweet expresses uncertainty or indifference toward Novo Nordisk with a series of shrug emojis.

Hims faces potential headwinds as patients transition from compounded alternatives to NVO's branded medication.

The tweet implies a positive outlook on Novo Nordisk through the use of celebratory emojis.

The author expects a potential price rebound for NVO following an upcoming investor call.

Novo Nordisk shares hit a multi-year low ahead of their AGM amid negative sentiment.

Novo Nordisk's triple G drug shows superior efficacy compared to Eli Lilly's, challenging the narrative that Novo lacks a strong pipeline.

Novo Nordisk is poised for growth due to record-breaking drug adoption and regulatory crackdowns on the illicit market.

NVO's key patent for semaglutide has expired in India, with $14 generics hitting the market, and China's patent is expiring soon. The introduction of ultra-cheap generics in the world's two most populous countries will severely undercut NVO's pricing power and capture international market share. The international patent cliff for NVO's blockbuster drugs creates a bearish headwind for the stock's global growth narrative. NVO's primary revenue and profit centers are the US and Europe, where patents remain intact and demand still vastly outstrips supply.

NVO trades at a forward P/E of 10 and P/S of 0.56 with a 69% ROE, while securing new FDA approvals (Wegovy HD) and operating in an $86B projected TAM. The market has overreacted to near-term headwinds (competition, guidance), creating a massive disconnect between the $37 share price and the company's intrinsic value (DCF $70-$97). Go long on NVO to capitalize on the extreme valuation mismatch, ongoing $15B buybacks, and upcoming catalysts like the AGM. Pricing pressure, Eli Lilly competition, FDA warning letters, and poor 2026 guidance.

A user noted that Novo Nordisk (NVO) is now trading in the $30s, a significant drop from its previous price range of $80-$100 when it was a popular buy on the subreddit. This massive price collapse (over 60% from its highs) indicates a severe negative catalyst or a fundamental breakdown in the company's story, turning it from a retail favorite into a falling knife. The stock has experienced a catastrophic decline from its former highs. Without a clear thesis for a turnaround, attempting to buy at this level is extremely risky. The prior bullish sentiment has completely evaporated. The stock could be oversold, and this might represent a bottom. However, the thread provides no information to support this, only highlighting the magnitude of the fall.

NVO is experiencing outsized downward movement on red market days, dropping harder than high-beta AI stocks. Despite being a pharma stock typically viewed as defensive, it is acting like a high-risk asset during this liquidity drain, catching holders off guard. Avoid holding NVO during this macro panic, as it is failing to provide the expected defensive stability. The stock could rebound if the broader market stabilizes or if sector rotation favors pharma once the initial panic subsides.

The author argues that Novo Nordisk's stock is not as cheap as it appears, implying it is overvalued and poised for underperformance.

Short Novo Nordisk ahead of a key patent expiration in a major market (India), which will introduce significant generic competition and pressure sales.

The market for obesity treatments and GLP-1 therapies is large and growing, with structural long-term demand. The current market price of Novo Nordisk (EUR 33.1) does not fully reflect this long-term growth potential, leading to an undervaluation compared to the author's calculated fair value (EUR 47.7). Novo Nordisk is undervalued because the market underestimates the size and durability of the obesity drug market, presenting a long-term buying opportunity. Increased competition, pricing pressure from payers, unexpected side effects from GLP-1 drugs, or a slowdown in market adoption could invalidate the thesis.

The author is downgrading Novo Nordisk and recommends selling the stock based on five specific reasons outlined in the linked article.

The author recommends buying Novo Nordisk on a pullback, anticipating future outperformance based on a "volume dominance" thesis.

The author believes Novo Nordisk will continue to face negative catalysts, viewing the latest FDA warning as another data point in an ongoing bearish narrative.